DelveInsight’s “Amyotrophic Lateral Sclerosis (ALS) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Amyotrophic Lateral Sclerosis Market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Amyotrophic Lateral Sclerosis Market drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Amyotrophic Lateral Sclerosis Market treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Amyotrophic Lateral Sclerosis (ALS) Market: An Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Amyotrophic Lateral Sclerosis belongs to a broader group of disorders known as motor neuron diseases, which are caused by the gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to the muscles throughout the body.
Amyotrophic Lateral Sclerosis can be either sporadic or genetic. The sporadic type is the most common and can affect anyone. The genetic or familial type is rarer. The terms familial and genetic mean that this type of Amyotrophic Lateral Sclerosis is inherited. In families who have genetic Amyotrophic Lateral Sclerosis, there is an up to 50% chance that each child will inherit the gene and develop the disease.
No one test can provide a definitive diagnosis of Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis is primarily diagnosed based on a detailed history of the symptoms and signs observed by a physician during physical examination along with a series of tests to rule out other mimicking diseases. However, the presence of upper and lower motor neuron symptoms strongly suggests the presence of the disease. Tests that may help diagnose Amyotrophic Lateral Sclerosis are electromyography (EMG), nerve conduction study (NCS), and magnetic resonance imaging (MRI).
Further tests to rule out other conditions may include blood and urine tests and a muscle biopsy. Medical problems that can produce similar symptoms to Amyotrophic Lateral Sclerosis, such as HIV, Lyme disease, multiple sclerosis (MS), the poliovirus, and the West Nile virus (WNV), should be considered when making a diagnosis.
Amyotrophic Lateral Sclerosis Market Key Facts
-
The United States accounts for the largest Amyotrophic Lateral Sclerosis market size compared to EU-4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan.
-
In the United States, the Amyotrophic Lateral Sclerosis market size is anticipated to rise from USD 369 million in 2021 during the forecast period.
-
Among the EU-4 countries, Germany had the largest Amyotrophic Lateral Sclerosis market size (USD 3 million) in 2021, while Spain had the smallest with USD 2 million.
-
Estimates show that the highest cases of Amyotrophic Lateral Sclerosis in the 7MM were in the United States, followed by EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan in the year 2021.
-
The US, in 2021 accounted for approximately 25,800+ diagnosed prevalent cases of Amyotrophic Lateral Sclerosis.
-
Among the EU-4 and the United Kingdom countries in 2021, Germany had the highest diagnosed prevalent cases of Amyotrophic Lateral Sclerosis with 5,300+ cases, followed by the UK (4,500+) and Italy (4,400+). In contrast, Spain had the lowest cases (3,200+) in 2021.
-
Current Amyotrophic Lateral Sclerosis Market dynamics are dominated by the use of RILUTEK, TIGLUTIK, EXSERVAN, NEUDEXTA, RADICAVA, RADICAVA ORS, RELYVRIO, and others (Anti-epileptic drugs, Opioids, NSAIDs, Diuretics, SSRIs, Antidepressants, etc.)
-
The therapies with the potential to get launched in the forecast period include Tofersen, ION363, NurOwn, Masitinib, and others. The launch of these therapies may increase market size in the coming years, assisted by an increasing patient pool of Amyotrophic Lateral Sclerosis patients.
Amyotrophic Lateral Sclerosis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Amyotrophic Lateral Sclerosis Market pipeline therapies. It also thoroughly assesses the Amyotrophic Lateral Sclerosis Market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Amyotrophic Lateral Sclerosis Market drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Amyotrophic Lateral Sclerosis Market Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Amyotrophic Lateral Sclerosis Market epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Amyotrophic Lateral Sclerosis Market epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Amyotrophic Lateral Sclerosis Market Epidemiology, Segmented as –
-
Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Gender-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Age-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Type-specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Mutation-Specific Distribution of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
-
Distribution Based on Site of Onset of Amyotrophic Lateral Sclerosis in the 7MM [2019–2032]
Amyotrophic Lateral Sclerosis Market Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Amyotrophic Lateral Sclerosis Market or expected to be launched during the study period. The analysis covers the Amyotrophic Lateral Sclerosis Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Amyotrophic Lateral Sclerosis Market drugs based on their sale and market share.
The report also covers the Amyotrophic Lateral Sclerosis Market pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Amyotrophic Lateral Sclerosis Market companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Amyotrophic Lateral Sclerosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
Amyotrophic Lateral Sclerosis Market Therapeutics Analysis
Currently, there is no cure for Amyotrophic Lateral Sclerosis and no effective treatment to halt, or reverse, the progression of the disease. The treatment landscape of Amyotrophic Lateral Sclerosis includes multidisciplinary care, such as physical therapy, speech therapy, dietary counseling, heat or whirlpool therapy, and others. Moreover, there are five drugs approved by the US FDA to treat Amyotrophic Lateral Sclerosis, namely RELYVRIO, Riluzole, NUEDEXTA, RADICAVA (IV and oral), and TIGLUTIK.
Medications are also prescribed to help manage symptoms of Amyotrophic Lateral Sclerosis, including pain, muscle cramps, stiffness, excess saliva and phlegm, and the pseudobulbar effect (involuntary or uncontrollable episodes of crying and/or laughing, or other emotional displays). Drugs are also available to help individuals with pain, depression, sleep disturbances, and constipation.
To further improve the treatment outlook, companies across the globe are thoroughly working toward the development of new treatment therapies for Amyotrophic Lateral Sclerosis. Some of the key players in the therapeutic market of Amyotrophic Lateral Sclerosis at a global level are Cytokinetics, Orphazyme, Orion, Brainstorm Cell Therapeutics, Biogen, AB Science, Ionis Pharmaceuticals, Clene Nanomedicine, Immunity Pharma, MediciNova, Biohaven Pharmaceuticals, and others.
Amyotrophic Lateral Sclerosis Market Companies Actively Working in the Therapeutics Market Include:
Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and many others.
Emerging and Marketed Amyotrophic Lateral Sclerosis Market Therapies Covered in the Report Include:
-
Tofersen: Biogen/Ionis Pharmaceuticals
-
RNS60: Revalesio Corporation
-
ANX005: Annexon
-
Masitinib: AB Science
-
NurOwn: Brainstorm-Cell Therapeutics
-
Gold Nanocrystals/CNM-Au8: Clene Nanomedicine
-
Verdiperstat: Biohaven Pharmaceuticals
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Amyotrophic Lateral Sclerosis Market Competitive Intelligence Analysis
4. Amyotrophic Lateral Sclerosis Market Overview at a Glance
5. Amyotrophic Lateral Sclerosis Market Disease Background and Overview
6. Amyotrophic Lateral Sclerosis Market Patient Journey
7. Amyotrophic Lateral Sclerosis Market Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Amyotrophic Lateral Sclerosis Market Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyotrophic Lateral Sclerosis Market Unmet Needs
10. Key Endpoints of Amyotrophic Lateral Sclerosis Market Treatment
11. Amyotrophic Lateral Sclerosis Marketed Therapies
12. Amyotrophic Lateral Sclerosis Market Emerging Drugs and Latest Therapeutic Advances
13. Amyotrophic Lateral Sclerosis Market Seven Major Market Analysis
14. Attribute Analysis
15. Amyotrophic Lateral Sclerosis Market Outlook (In US, EU5, and Japan)
16. Amyotrophic Lateral Sclerosis Market Companies Active in the Market
17. Amyotrophic Lateral Sclerosis Market Access and Reimbursement Overview
18. KOL Views on the Amyotrophic Lateral Sclerosis Market
19. Amyotrophic Lateral Sclerosis Market Drivers
20. Amyotrophic Lateral Sclerosis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-market-forecast
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Chronic Refractory Gout Market
“Chronic Refractory Gout Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Refractory Gout market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Chronic Refractory Gout market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research